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ly 3, 2013.he goal of this study was to examine the impact of calculation-window duration on lifespan gain (as observed in
trials) and on who gains most.Background The landmark trials of biventricular pacing (cardiac resynchronization therapy [CRT]) typically ran for <1 device
battery life, and they may therefore underestimate lifespan beneﬁt over longer durations.Methods We conducted a meta-analysis of biventricular pacing trials to calculate lifespan gained: ﬁrst, within the duration of
randomized controlled trial data up to 2 years; second, over a 5-year typical battery life; and third, over >1 battery
life. Importantly, we applied the Gompertz method for age-related increase in mortality from non–CRT-preventable
causes.Results Five landmark trials (COMPANION [Comparison of Medical Therapy, Pacing, and Deﬁbrillation in Heart Failure],
CARE-HF (CArdiac REsynchronization–Heart Failure), MADIT-CRT [Multicenter Automatic Deﬁbrillator Implantation
Trial With Cardiac Resynchronization Therapy], REVERSE [Resynchronization Reverses Remodeling in Systolic
Left Ventricular Dysfunction], RAFT (Resynchronization–Deﬁbrillation for Ambulatory Heart Failure)) provided data
for 2 years (6,561 patients), with an average hazard ratio of 0.71. Lifespan gained across all trials increased
nonlinearly with time from 0.1 month at 1 year, to 0.5 month at 2 years, and a projected 6.5 months at 5 years
(65 times more than at 1 year). After multiple devices, it reached 14 months, involving on average 1.6 devices
(i.e., 8.8 months per device implanted). Moreover, while over a short window (e.g., 2 years), lower-mortality patients
may gain less than higher-mortality patients (1.4 vs. 2.3 months), their positions reverse by 15 years (16.0 vs.
13.7 months).Conclusions Lifespan gain from biventricular pacing rises nonlinearly with time. Early on, higher-risk patients exhibit more gain,
but later, lower-risk patients exhibit more gain. Quantifying gain over less than a patient’s lifetime underestimates
lifespan gain. Over the ﬁrst 1 or 2 years, lower-risk patients may seem to gain less, although they may ultimately be
the ones who gain the most. (J Am Coll Cardiol 2013;62:2406–13) ª 2013 by the American College of Cardiology
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Lifespan gain can be evaluated from trial data. It is the
area between survival curves for the device and nondevice
arms. However, trials rarely run to the lifespan of the device
and, even if they do, staggered enrollment means few
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2407patients with long follow-up, making the later parts of the
area between survival curves noisy. Whether addressing lifespan
gain over a shorter period is acceptable has not been determined
for biventricular pacing. It is also unclear whether a single device
should be considered, rather than a commitment to sequential
devices. Competing risks from other causes of death can be
expected to rise with aging, but how much does this
attenuate the lifespan beneﬁt estimated per device?
In the current study, we examined the impact of time
window over which lifespan gain is quantiﬁed, on the size of
that lifespan gain, and on who gains most. We conducted
this analysis in 3 ways. First, within the duration of
randomized controlled trials of biventricular pacing, in terms
of lifespan gain per patient; second, over a typical battery
life of a biventricular pacemaker; and third, over >1 battery
life, quantiﬁable as lifespan gain per patient or per device.Figure 1
Graphic Showing How Lifespan Gained Is Related
to Survival Curves
Horizontal distance between the curves is lifespan gained. The distance is often
greater farther down the graph (less sick patients, who survived longer). The total
area between the curves is the average lifespan gained per patient.Methods
Search strategy. We searched MEDLINE from inception
to March 2013 using a combination of key words, including
cardiac resynchronization therapy, biventricular pacemaker,
mortality, survival, and randomized controlled trial. We also
searched the bibliographies of published systematic reviews
(3,4).
Trials that compared biventricular pacing against no
biventricular pacing and reported Kaplan-Meier survival
curves for at least 6 months were identiﬁed. Trials with
implantable cardioverter-deﬁbrillator therapy were not
excluded as long as it was present in both study arms.
Data analysis. We quantiﬁed at 3-month intervals the
segmental area between the 2 curves (Fig. 1) and the
cumulative area representing lifespan gained per patient up
to that time.
Effect of analysis duration on lifespan gained. The
shortest duration of survival curves presented by all trials was
2 years. To examine how lifespan gained changed with
follow-up duration, we calculated for each trial the lifespan
gained at each time point as a proportion of lifespan gained
in that trial at 2 years. The results for different trials were
then scaled to permit easy comparison between trials with
different mortality rates (5).
Calculated survival gain for the duration of 1 device. Ha-
zard ratios reported by trials are the most precise estimate of
the mortality effect of the decision to implant. Making the
assumption that they remain similar during the life of 1
device, we then calculated survival curves and lifespan gain to
5 years.
Calculated survival gain for >1 sequential device. It is
excessively pessimistic to halt analysis at the duration of 1
device (5) because it ignores the subsequent lifespan gain of
patients who were enabled to survive until then. Conversely,
during use of subsequent devices, patients are older and
have more competing risks that a biventricular pacemaker
may not reduce. Thus, we partitioned risk into that on which
the pacemaker might have a physiological effect and thaton which it would not. The
pacemaker-relevant risk com-
ponent was conservatively consid-
ered to remain constant with age,
and the relative risk reduction for
that component was also consid-
ered constant with age. In contrast,
the nonpacemaker-relevant risk
component was made to rise
progressively with time in the standard Gompertz manner (6),
and the risk reduction for that component was kept at zero.Results
Characteristics of included trials. Seven trials met the
criteria of comparing biventricular pacemaker implantation
with no such implantation and publishing Kaplan-Meier
survival curves. Two were excluded because follow-up was
6 months (7,8). The 5 eligible trials (9–13) totaled 6,561
patients (Table 1). All provided survival curves for at least
2 years. For the COMPANION (Comparison of Medical
Therapy, Pacing, and Deﬁbrillation in Heart Failure) trial,
we used only the CRT-pacemaker and no-device arms.
Lifespan gained from device implantation averaged
across all trials. The average pattern of lifespan gained,
weighted according to study size between 0 and 24 months
across all trials, is shown in Figure 2. Because the lifespan
gain curve for each trial was rescaled to run from 0 at 0 year
to 100% at 24 months, the averaged curve also does the
same. The shape was nonlinear, with a slow early develop-
ment and later progressively faster development of life-years
gained with time. The lifespan gain at 24 months was >4
times the lifespan gain at 12 months.
Table 1 Characteristics of Included Studies
Study, Year (Ref. #) Trial Participants n
Mean Follow-Up
(months) % Male
Mean Age
(yrs)
Ischemic
Etiology
(%)
NYHA
Functional
Class
LVEF
(%)
Mean QRS
Duration
(ms)
Hazard Ratio:
Mortality
Hazard Ratio:
Hospitalization
CRT versus medical therapy
CARE-HF, 2005 (9) Patients with NYHA class III or IV
heart failure and with
LVEF 35%, a left ventricular
end-diastolic dimension of at
least 30 mm (indexed to
height), and a QRS interval
>120 ms were randomly
assigned to optimal medical
therapy or CRT-P
813 29.4 73 67 38 III to IV 25 160 0.64 (0.48–0.85) 0.61 (0.49–0.77)
COMPANION, 2004 (11) Patients with NYHA class III or IV
ischemic or dilated
cardiomyopathy and QRS
duration >120 ms were
randomly assigned in a 1:2:2
ratio to optimal medical
therapy, CRT-P, or CRT-D
1,520 16.5 (median) 68 67 55 III to IV 22 160 0.76 (0.58–1.01)
CRT þ ICD versus ICD alone
REVERSE, 2008 (10) Patients with NYHA class I or II
heart failure with CRT-P or
CRT-D and QRS 120 ms and
LVEF 40% were randomly
assigned to CRT-on versus
CRT-off
610 12 82 61 43 I to II 28 156 0.40 0.39
MADIT-CRT, 2009 (13) Patients with NYHA class I or II
ischemic or nonischemic
cardiomyopathy, LVEF 30%,
a QRS duration of 130 ms
Patients were randomly
assigned in a 3:2 ratio to receive
CRT plus an ICD or an ICD alone
1,820 29 75 65 55 I to II 24 1.00 (0.69–1.44) 0.59 (0.47–0.74)
RAFT, 2010 (12) Patients with NYHA class II or III
heart failure with LVEF 30%
and intrinsic QRS
duration 120 ms or a paced
QRS duration 200 ms were
randomly assigned to either an
ICD alone or an ICD plus CRT
1,798 40 83 66 67 II to III 23 158 0.75 (0.62–0.91) 0.68 (0.56–0.83)
CARE-HF ¼ CArdiac REsynchronization–Heart Failure; COMPANION ¼ Comparison of Medical Therapy, Pacing, and Deﬁbrillation in Heart Failure; CRT ¼ cardiac resynchronization therapy; CRT-D ¼ CRT-deﬁbrillator; CRT-P ¼ CRT-pacemaker; ICD ¼ implantable cardioverter-
deﬁbrillator; LVEF ¼ left ventricular ejection fraction; MADIT-CRT ¼ Multicenter Automatic Deﬁbrillator Implantation Trial With Cardiac Resynchronization Therapy; NYHA ¼ New York Heart Association; RAFT ¼ Resynchronization–Deﬁbrillation for Ambulatory Heart Failure;
REVERSE ¼ Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction.
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Figure 2
Pattern of Growth of Lifespan Gain From Device
Implantation Weighted According to Study Size and
Averaged Across All Trials
Lifespan gained calculated at each time point as proportion of lifespan gained at
24 months. Bars show SEM.
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From the trial data, Table 2 shows the lifespan gained at 1,
2, 3, and 5 years after device implantation. In parallel is
shown the number of devices needed to be implanted
(NNT) to gain 1 life-year. Lifespan gained rises progres-
sively, and NNT falls progressively, for progressively longer
time windows. The nonlinear pattern evident across all
studies in aggregate (Fig. 2) is also visible in all 5 individual
trials (Table 2, Fig. 3).
Figure 3 illustrates the similar nonlinear pattern of life-
span gained across all 5 trials: slow early and progressively
faster later. Within the 2 years available in all trials, absolute
life-years gained is much larger in trials in advanced heart
failure (COMPANION and CARE-HF) than in those in
milder heart failure (MADIT-CRT [Multicenter Auto-
matic Deﬁbrillator Implantation Trial With Cardiac
Resynchronization Therapy] and REVERSE [Resynchro-
nization Reverses Remodeling in Systolic Left Ventricular
Dysfunction]), as shown in the middle row of panels.
However, when the curves showing development of life-
years gained are re-scaled (bottom panels), a similar curvi-
linear progression is seen across all 5 trials.Table 2 Lifespan Gained and NNT to Gain 1 Life-Year Compared With
Lifespan Gained/Device Implanted (months)
1 Year 2 Years 3 Years 5 Ye
REVERSE 0.00 0.40
CARE-HF 0.16 0.82 2.01
COMPANION 0.12 0.84 1.62
MADIT-CRT 0.00 0.09 0.10
RAFT 0.13 0.37 0.77 2.5
NA ¼ not assessable; NNT ¼ number-needed-to-treat; other abbreviations as in Table 1.Calculated survival gain for >1 sequential device. In
practice, patients who receive 1 device and survive its entire
battery life will usually have it replaced. However, the hazard
ratio with extended aging will depend on the extent to which
deaths are heart failure related. If almost all mortality is heart
failure related, then even substantial scaling up of the few
non-heart-failure–related deaths with aging might not
greatly inﬂuence the overall hazard ratio.
For example, in CARE-HF, one-quarter of deaths were
noncardiac related. To achieve its overall 0.64 hazard ratio,
the hazard ratio for cardiac death would have been w0.52
because (0.75  0.52) þ (0.25  1) ¼ 0.64. Had the
population had a greater proportion of noncardiac deaths
(e.g., 50%), then the overall hazard ratio might have been
(0.50  0.52) þ (0.50  1) ¼ 0.76. Figure 4 shows the
results for 3 different possibilities for hazard ratios after trial
end. For Figure 4A, annual mortality is initially 12.6%
(annual mortality at 1 year in CARE-HF [9]) and initially
one-quarter of this is non-heart-failure related, and the
absolute rate scales up by a factor of 1.1 with every year of
aging, as is typical (6). For Figures 4B and 4C, initially one-
half and three-quarters of mortality is non-heart-failure
related and has the same age scaling.
Figure 5 shows a perhaps surprising phenomenon. For the
same hazard ratio, the patient group with the highest baseline
risk (Fig. 5F) exhibited more lifespan gain than the group at
lower baseline risk (Fig. 5D), at the early 5-year time point.
However, by 15 years, the situation has reversed. The reason
for this ﬁnding is that a lower-risk group has more survivors at
5 years than a high-risk group and so continuing the calcu-
lation for longer reveals more additional lifespan gain. In our
example, over a short window of 2 years, using the average
hazard ratio of all 5 trials (0.71), those with a lower mortality
risk (10%) would gain 1.4 months while those at higher
mortality (20%) would gain much more (2.3 months). By 15
years, however, the gain in the lower-risk group increased to
16.0 months, whereas the gain in the higher-risk group
reached only 13.7 months.
Discussion
Which risk stratum of patients gains the most lifespan from
biventricular pacemaker implantation depends on the time
window over which gain is assessed. Over a short window,
higher-risk patients may gain more lifespan than lower-riskDuration of Follow-Up After Device Implantation
Size of NNT to Gain 1 Life-Year
ars 1 Year 2 Years 3 Years 5 Years
NA 30.1
75.8 14.6 6.0
101.8 14.4 7.4
NA 137.1 119.8
2 91.3 32.7 15.5 4.8
Figure 3 Survival, Life-Years Gained and Life-Years Gained Re-Scaled, for All 5 Trials
Kaplan-Meier curves (upper panels), life-years gained (middle panels) and life-years gained as a proportion of gain at 2 years (lower panels). All 5 trials show a gradual,
nonlinear increase in lifespan gain with time. CARE-HF ¼ CArdiac REsynchronization–Heart Failure (9); COMPANION ¼ Comparison of Medical Therapy, Pacing, and Deﬁbrillation
in Heart Failure (11); MADIT-CRT ¼ Multicenter Automatic Deﬁbrillator Implantation Trial With Cardiac Resynchronization Therapy (13); RAFT ¼ Resynchronization–Deﬁbrillation
for Ambulatory Heart Failure (12); REVERSE ¼ Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction.
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Thus, even well-designed, well-conducted, and well-
reported trials of patients at lower annual risk such as
MADIT-CRT (13) and REVERSE (10) ended after
exposing only a tiny fraction of the full lifespan gain available
from biventricular pacing.
Appropriate index of beneﬁt depends on disease and
intervention. We focused on lifespan gained, because it is
relevant to patients, and on lifespan gained per device
implanted because of its health/economic importance. More
common metrics such as NNT and absolute risk reduction
have the disadvantage of implicitly assuming no beneﬁt
after trial end; disease-modifying interventions may give
continued beneﬁt (14), which they do not capture (15). The
choice of statistical metric depends on disease and inter-
vention. For example, for brief therapies with immediate
consequences (e.g., antibiotics for acute infection), NNT
may be the most appropriate metric (16). For lifelong
treatment with progressively accumulating cost such as drug
therapy for chronic disease, a more appropriate metric is
years-needed-to-treat to gain 1 life-year (15). Calculation of
years-needed-to-treat must address survival gain in the
posttrial period to give a correct quantiﬁcation. For on–off
interventions that may have sustained effect on mortality
(e.g., device implantation), lifespan gain per device may be
the most appropriate metric. In addition to assessing beneﬁt
in the posttrial period, this method also begins to address
cost-effectiveness.Impact of time-window in assessing lifespan gain. Trials
rarely continue with randomization intact until survival is
zero in both arms; therefore, the observed lifespan gain
within trials is much less than the potential gain. The only
practical way of assessing lifespan gain over a satisfactorily
long period is with the use of modeling, but this method
must take into account the progressive increase in
noncardiac mortality. We used the Gompertz method
for this.
At 1 year, the lifespan gain was only (10) 0.1 month,
but by 2 years this had grown to 0.5 month, by 5 years to
6.5 months, and by 15 years to 13.7 months. Such
calculations are dependent on the hazard ratio being
preserved in the longer term, supported by the CARE-HF
(17) ﬁnding of no attenuation of hazard ratio in its
extension period.
Impact of patient group studied in assessing lifespan
gain. Trials in patients at high mortality risk may have
greater statistical power, but these patient groups may not be
those who gain the greatest lifespan beneﬁt over their entire
lifetime, since their lifetime may be short (2). Conversely,
trials of the same duration in patients at lower mortality risk
are inherently less powered, but these patient groups may
gain the greatest increment in lifespan if given a lifetime of
biventricular pacing. Thus, even though CARE-HF and
COMPANION were the trials reporting the most encour-
aging mortality effects from biventricular pacing, we
should not assume that REVERSE and MADIT-CRT
Figure 4 Impact of Extent of Competing Mortality Risks on Lifespan Gain From Biventricular Pacing
As the proportion of non-heart-failure–related mortality is increased from one-quarter (A, D) to one-half (B, E) to three-quarters (C, F), the Kaplan-Meier curves (A to C) become
progressively closer together. Correspondingly, lifespan gain becomes progressively smaller (D to F). This is true at every timepoint and regardless of whether it is calculated per
patient (red curve) or per device (black curve).
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2411populations, if given a lifetime of pacing, would not exhibit
a lifespan beneﬁt.
When faced with patients such as those of REVERSE or
MADIT-CRT, we should consider carefully whether it is
wise to delay device implantation until they reach the
CARE-HF/COMPANION stage of disease (18). Delaying
may cause the curves to diverge quicker, but our analysis
indicates it may also miss the majority of the opportunity for
lifespan gain.
Although the etiology of heart failure affects lifespan gain,
quantitative analysis is limited because Kaplan-Meier plots
are not available for these subgroups. Gain is likely to be
greater for patients with nonischemic heart failure than
ischemic heart failure.
Need for modeling to assess the cost-effectiveness of
biventricular pacing. Previous analyses (19–21) exploring
the cost-effectiveness of biventricular pacing have used trial
data to estimate the incremental cost-effective ratios.
Device implantation has front-loaded costs, and using trial
data only will therefore tend to underestimate cost-
effectiveness by concentrating on the early period when
cost is already fully exposed but lifespan gain is only partlyrevealed. This pattern has also been observed for
implantable deﬁbrillators (22,23).
Study limitations. Our study analyzed survival to 2 years
because this was the period for which all the trials showed
Kaplan-Meier survival data. We used the Gompertz
method to address posttrial survival although there are
alternatives, including the Deale method (24). Modeling
post-trial survival can only provide an estimate of the
potential beneﬁt of an intervention. However, prolonged
clinical trials are expensive, and it may be ethically unac-
ceptable to withhold devices from patients in the control
arm long after the device is proven beneﬁcial for mortality.
Modeling may therefore be the best way of quantifying
ultimate survival gain.
Our analysis used only total mortality data rather
than attempting to assess quality of life. For formal
cost-effectiveness analysis, it is usual to assess QALYs.
Because patients with milder heart failure often have
higher quality of life, each incremental life-year gained for
them would contribute more QALYs than a life-year
gained in a patient with more severe disease. Therefore,
this effect of patients with milder disease showing more
Figure 5 Which Risk Group Gains the Most?
The answer to this question depends on the time window over which the evaluation is made. The panels show progressively increasing mortality: 10% (A, D), 15% (B, E), and
20% (C, F); in all cases, one-quarter of the mortality is non-heart-failure related and the same initial hazard ratio from CARE-HF (0.64) is used. At the 5-year time point, the
highest-risk group (A, D) gained the most lifespan, but at the 20-year time point, the lowest-risk group (C, F) gained the most.
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analyzed with QALY data.
Conclusions
Lifespan gain from biventricular pacemaker implantation
rises rapidly with time and much more than linearly. It
continues to grow as long as patients continue to survive and
are free of competing mortality risks. For this reason,
although higher-risk patients may show clear gain at early
time points when lower-risk patients (e.g., the MADIT-
CRT [13] and REVERSE [10] cohorts) show no signiﬁ-
cant gain, this situation may reverse with time.
Such analytical approaches to quantifying lifespan gain
may be useful because designing trials to directly observe
lifespan gain in its entirety would need maintenance of
randomization for decades.
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